Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.

Deshmukh AD, Kesselheim AS, Tsacogianis T, Rome BN

DOI: 10.1002/pds.70009
Published: 2024 Oct
Container: Pharmacoepidemiology and drug safety
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/pds.70009,
  title = {Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.},
  author = {Deshmukh AD and Kesselheim AS and Tsacogianis T and Rome BN},
  year = {2024},
  journal = {Pharmacoepidemiology and drug safety},
  doi = {10.1002/pds.70009},
  url = {https://doi.org/10.1002/pds.70009}
}

RIS

TY  - JOUR
TI  - Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.
AU  - Deshmukh AD
AU  - Kesselheim AS
AU  - Tsacogianis T
AU  - Rome BN
PY  - 2024
JO  - Pharmacoepidemiology and drug safety
DO  - 10.1002/pds.70009
UR  - https://doi.org/10.1002/pds.70009
ER  -

APA

AD, D., AS, K., T, T., & BN, R. (2024). Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications.. Pharmacoepidemiology and drug safety. https://doi.org/10.1002/pds.70009

Source records

pubmed · retrieved 2026-09-26T11:14:06.664Z